Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking ...

While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health ...

Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...